Previous 10 |
Marizyme, Inc. Appoints Dr. Neil J. Campbell, as CEO, President and Member of Board of Directors Veteran Life Sciences Executive and Investor Brings 35+ Years' Experience PR Newswire JUPITER, Fla., Nov. 6, 2020 JUPITER, Fla. , Nov. 6, 2020 /PRNewswire/ --...
JUPITER, FL / ACCESSWIRE / October 27, 2020 / Marizyme, Inc. (OTCQB:MRZM) ("Marizyme" or the "Company"), an integrated life sciences company, announced today that it has signed a binding letter of intent with SBH Nutrition Science LLC ("SBH") to develop pet therapeutic products using Marizym...
JUPITER, FL / ACCESSWIRE / October 9, 2020 / Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB:MRZM) is a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications. Today, Marizy...
JUPITER, FL / ACCESSWIRE / September 29, 2020 / Marizyme, Inc. ("Marizyme" or the "Company"), a publicly traded (OTCQB:MRZM) company focused on acquiring late-stage drug and medical device assets announced today that it has completed the acquisition of all or substantially all of the Somahlu...
DAVENPORT, Fla. , Oct. 11, 2019 /PRNewswire/ -- Marizyme, Inc. ("Marizyme" or the "Company"), a publicly traded (OTC:MRZM) company focused on acquiring late-stage drug assets to develop for use in the acute care space, announced today that they have agreed to exclusively distribute Somahl...
Sacramento, CA, March 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Spotlight Growth has published new content on Marizyme, Inc. ("Marizyme" or the "Company") (OTC Pink: MRZM), a biotechnology company focused on its clinically-tested and patented use of protease therapeutic platform...
FORT COLLINS, CO / ACCESSWIRE / March 18, 2019 / Marizyme, Inc. (''Marizyme'' or the ''Company''), a publicly traded (OTC PINK: MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space and related areas, announced today that they signed a Letter of Intent ...
FORT COLLINS, CO / ACCESSWIRE / March 15, 2019 / Marizyme, Inc. ("Marizyme" or the "Company"), a publicly traded (OTC PINK: MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space for development and commercialization, announced today that they have recei...
Sacramento, CA, March 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Spotlight Growth has published new content on Marizyme, Inc. (“Marizyme” or the “Company”) (OTC Pink: MRZM), a biotechnology company focused on its clinically-tested and patented use of p...
News, Short Squeeze, Breakout and More Instantly...
JUPITER, FL - ( NewMediaWire ) - May 06, 2024 - Marizyme, Inc. (OTCQB: MRZM) is pleased to announce that its flagship product DuraGraft ® will no longer require refrigerated storage and will be able to be stored at controlled room temperatures of 20 o C-25 o C allowing it to be ...
JUPITER, FL - ( NewMediaWire ) - April 16, 2024 - Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN ) to advance the commercial...
--News Direct-- Marizyme Inc CEO David Barthel joined Steve Darling from Proactive to provide an exciting update on the remarkable progress that the company has achieved in recent months. Among the standout developments is the approval received from the US Food and Drug Administration for...